Loading
Loading
Brain-Computer Interface Patients Face Abandonment When Manufacturers Fail — and No Regulatory Framework Prevents It
Implantable brain-computer interfaces (iBCIs) are emerging medical devices that create direct communication pathways between the brain and external technology. Unlike traditional implants such as pacemakers, iBCIs depend on continuous software support, cloud connectivity, firmware updates, and algorithmic calibration to function. If the manufacturer goes bankrupt, pivots its business, or simply stops supporting the product, the patient is left with a non-functional or degrading implant in their brain with no pathway for continued care. The FDA's current regulatory framework does not require manufacturers to establish contingency plans for device support, data handover, or explantation funding in the event of company failure. As commercial iBCI development accelerates — Neuralink, Synchron, Paradromics, Blackrock Neurotech — this gap will affect an increasing number of patients.
Current patient numbers are small (dozens in clinical trials), but the market is projected to grow rapidly as commercial authorizations are obtained. Each affected patient faces the risk of carrying a non-functional implant that cannot be safely explanted without risk of brain damage, or that degrades in ways that affect neural function. The BCI industry follows the venture-capital startup model where company failure rates are high, yet patients who receive implants during clinical trials or early commercialization are uniquely vulnerable because the device cannot function without manufacturer-provided software and support. The precedent being set now will determine the framework for thousands of future patients.
The FDA's 2021 BCI guidance provided recommendations for nonclinical testing and IDE study design but did not address long-term manufacturer support obligations, software dependency management, or patient abandonment scenarios. Cases have already emerged of patients with abandoned neurotechnology implants who lost device functionality when research teams dissolved or companies failed, facing medical complications and data security vulnerabilities. The FDA lacks explicit statutory authority to mandate post-approval manufacturer support obligations beyond adverse event reporting and post-approval studies. Requiring financial escrow or source code deposit would be unprecedented in device regulation. The startup ecosystem resists binding long-term obligations that increase burn rate and reduce investment attractiveness. No insurance or government program exists to fund explantation or continued device support after manufacturer failure. The surgical risks of explanting a chronically implanted brain device may exceed the risks of leaving it in place, trapping patients with non-functional hardware.
A regulatory framework requiring BCI manufacturers to establish contingency plans before market authorization — including source code escrow, encryption key handover procedures, minimum support duration commitments, and financial provisions for explantation. An industry consortium model (similar to nuclear decommissioning funds) where BCI manufacturers pool resources to guarantee patient support. Open-architecture BCI designs with standardized interfaces that could be maintained by third parties if the original manufacturer fails. The precedent from cochlear implants — where market consolidation and product discontinuation are common — provides both cautionary examples and potential models for continuity frameworks.
A student team could draft a model regulatory framework for BCI manufacturer continuity obligations, drawing on precedents from nuclear decommissioning funds, pharmaceutical orphan drug requirements, and software escrow agreements. Another entry point would be designing an open-architecture BCI firmware platform with standardized APIs that would allow third-party maintenance if the original manufacturer ceases operations. A policy/engineering hybrid team could analyze current informed consent documents from BCI clinical trials and identify gaps in communicating long-term software dependency risks. Teams with backgrounds in regulatory science, bioethics, embedded systems, or health policy would be well-suited.
- FDA Guidance on Implanted BCI Devices (2021) focused on biocompatibility, electrical safety, sterility, and clinical study design — none of the identified gaps regarding long-term software support or manufacturer failure contingencies were addressed. - Knowing Neurons (2024) documented real cases of patients with abandoned neurotechnology implants. Frontiers in Human Neuroscience (2025) identified regulatory gaps in IRB and FDA oversight of implanted BCI human subjects research. - Neuralink received FDA Breakthrough Device Designation and initiated human trials in 2024. Synchron has enrolled patients in a pivotal trial for its endovascular BCI. No manufacturer has publicly committed to binding long-term support obligations. - The "window" temporal tag reflects that the BCI industry is still in early commercialization — establishing continuity frameworks now (before thousands of patients are implanted) is far more tractable than retrofitting them later. - Related to broader patterns of software-dependent medical devices where the device lifecycle exceeds the manufacturer's software support cycle.
FDA Guidance, "Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation — Non-Clinical Testing and Clinical Considerations," 2021, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/implanted-brain-computer-interface-bci-devices-patients-paralysis-or-amputation-non-clinical-testing; supplemented by Knowing Neurons, "The Aftermath of Abandoned Neurotech" (2024); Frontiers in Human Neuroscience, "Mind the gap: bridging ethical considerations and regulatory oversight in implantable BCI" (2025). Accessed 2026-02-19.